Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusConfronting the Care Delivery Challenges Arising from Precision MedicineOff-label use of targeted therapies in oncologyTreatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine TrialsIntegrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsMolecular pathology of cancer: how to communicate with diseaseFuture paradigms for precision oncologyOptimizing adjuvant therapy and survivorship care of stage III colon cancer.Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Findings made in gene panel to whole genome sequencing: data, knowledge, ethics - and consequences?How may targeted proteomics complement genomic data in breast cancer?Giving Up on Precision Oncology? Not So Fast!Genomic mutation-driven metastatic breast cancer therapy: a single center experienceCorrelation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implicationsDistribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer.Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancerReversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targetsEvolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean InstitutionSequencing Strategies to Guide Decision Making in Cancer Treatment.Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewTissue-specific tumorigenesis: context matters.Data resources for the identification and interpretation of actionable mutations by clinicians.Precision oncology based on omics data: The NCT Heidelberg experience.Clinical trial designs incorporating predictive biomarkers.Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineThe current use and attitudes towards tumor genome sequencing in breast cancer.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.New generation of breast cancer clinical trials implementing molecular profiling.Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.Expansion platform type II: testing a treatment strategy.Comparative genomic analysis of primary tumors and metastases in breast cancer.Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples.Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.Institutional implementation of clinical tumor profiling on an unselected cancer population.Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.The cost of cancer care is not related to its outcomes
P2860
Q26738986-B9D7D2E0-4222-414A-A66A-6369A27AB596Q26740184-B8344B3D-756E-4C36-B2D5-1DA5928CD041Q26747282-21CDFE56-AB96-4109-BB7C-5D86E80ABF31Q26747685-C24A9B8F-3E92-49E5-8D2F-9B4E1E11140CQ26776394-4B6FFE19-A712-4AE0-AC67-FC02840BE26AQ28066709-8B015A89-E7E6-4A95-94AD-7D77C0F4C7C8Q28076360-734C99D0-BDC6-44DC-A116-66864A565155Q28078745-F7DC46AE-0211-4BA6-9274-124B68FB43E8Q30249616-CE604EBC-49CC-451B-8E51-B57336E1804EQ30826387-8081D458-3BB5-4C23-B845-0989A38F6C08Q31114379-D902CF1A-904B-45C9-A0A1-67E7463AB2D4Q31140924-A8D9D1ED-3AF2-43F9-A3EF-CCA773C2331AQ33648034-C252207F-8880-46F8-BCB0-8FAA7CD5EF5FQ33688687-4C61E30E-1BBB-4CD4-B99F-18F46C1AB217Q33779585-0999F4DE-EA59-4B8F-920A-8AE554C19F5CQ33833750-93BED361-C2C2-4205-90D6-25A12BA6117BQ33888813-743173E7-F92E-46D6-B35D-6E94D24E7173Q33903831-C265BF75-CEF5-4C2C-9F08-F2901FA80E05Q34529131-F940EC93-D842-4AA3-85C7-9055030A445FQ35997083-406BF9A4-87DE-49EB-9001-A996845D2945Q36214189-18A3DE09-FB94-4BD2-B041-CE5D4E82ED65Q36233937-1E4E4F30-F660-4AC3-8949-44C722191A97Q36270115-1262CA4D-A298-4229-BE93-99D3599DCD0FQ36296335-C01E9706-D9DC-41E5-9B13-2D9142C1B67AQ36317783-EBD33A8B-1265-4FE0-B3DC-26C91EF349DCQ36396606-ED600D5F-30E6-4303-88D7-FC83974E0434Q36534713-9F123039-D4FB-46DF-A58D-018494E07C3FQ36562114-D0A8E582-CE1B-42D4-8A0B-A839618D1F65Q36638214-D2D7C695-C598-415D-A9AF-D717162B0F2FQ37017110-5D17F276-B182-44B1-84E7-B3CBAF141443Q37094064-692D0CC3-4068-4D0B-94A4-C6E925B72E27Q37164556-CEF378F2-9ABC-44DA-AE13-760C9FD00CDCQ37181647-4C9567D1-06D1-4CD8-A0B8-B34A54BF6DD0Q37317214-6DBC454F-737D-461C-A77A-C4F5F9826343Q37317218-CBB0C691-0050-4A66-951B-4A013014BF40Q37360550-F31087D5-3C04-4088-95F3-144A8B9A54B6Q37416678-048EF6C0-2601-4401-86FD-C8DBB26CC4E0Q37417570-52F0C2F1-8AE6-4DEE-BB8E-29CA06CDFF7FQ37422731-69813069-1225-46F2-8C0B-10E369BFC16AQ37458769-D745C07E-0E2F-4E0B-A8D0-C7D7DB303981
P2860
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Molecularly targeted therapy b ...... sed, controlled phase 2 trial.
@en
type
label
Molecularly targeted therapy b ...... sed, controlled phase 2 trial.
@en
prefLabel
Molecularly targeted therapy b ...... sed, controlled phase 2 trial.
@en
P2093
P50
P1433
P1476
Molecularly targeted therapy b ...... sed, controlled phase 2 trial.
@en
P2093
Anthony Gonçalves
Coraline Dubot
Cécile Mauborgne
Céline Gavoille
David Gentien
Ivan Bièche
Jean-Pierre Delord
Marie-Ange Massiani
Marie-Paule Sablin
Mario Campone
P304
P356
10.1016/S1470-2045(15)00188-6
P577
2015-09-02T00:00:00Z